Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Biobusiness Briefs
  • Published:

Market watch

Where is personalized medicine in industry heading?

Nature Reviews Drug Discovery volume 14, pages 812–813 (2015)Cite this article

Subjects

As more is understood about disease pathways and inter-patient variability in the ways that these pathways are affected by drugs, personalized medicine (now also referred to as precision medicine) is becoming an increasingly powerful tool for medical practice, an urgent mission for regulatory agencies overseeing public health, and a natural trajectory for biotechnology and pharmaceutical companies.

What part is industry playing to make precision medicine a reality? In 2010, the Tufts Center for the Study of Drug Development (CSDD) in Boston, USA, surveyed 16 major biotechnology and pharmaceutical companies that were identified as pursuing pharmacogenomic drug development strategies, to assess progress and prospects for the implementation of personalized medicine (Nat. Rev. Drug Discov. 11, 178; 2012). We have now followed up this study with a survey of 15 leading companies (Tufts CSDD Impact Report 17(3); 2015) that manufacture personalized medicines (listed by the Personalized Medicine Coalition or identified from public sources; see Supplementary information S1 (box) for details). Here, we present the latest survey data and analyse trends from the two surveys.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Personalized medicine in industry: survey responses.

Author information

Authors and Affiliations

  1. Tufts Center for the Study of Drug Development, Tufts University, 1 92 South Street, Suite 550, Boston, 02111, Massachusetts, USA

    Christopher-Paul Milne, Joshua P. Cohen & Ranjana Chakravarthy

Authors
  1. Christopher-Paul Milne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua P. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ranjana Chakravarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher-Paul Milne.

Ethics declarations

Competing interests

The authors are employed by the Tufts Centre for the Study of Drug Development (Tufts CSDD), a non-profit, academic unit within Tufts University School of Medicine. Some of Tufts CSDD's general funding is provided by unrestricted grants from biopharmaceutical companies and associated service providers. The funding for the 2010 and 2015 surveys was provided in part by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Personalized Medicine Coalition (PMC), respectively.

Related links

PowerPoint slides

Supplementary information

Supplementary information S1 (box)

Survey methodology (PDF 122 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Milne, CP., Cohen, J. & Chakravarthy, R. Where is personalized medicine in industry heading?. Nat Rev Drug Discov 14, 812–813 (2015). https://doi.org/10.1038/nrd4759

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4759

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research